Cardiovascular · ACE InhibitorSafety Signalregulatorynear-term

Crescent Pharma recalls Ramipril 5mg capsules due to manufacturing error

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Crescent Pharma Limited2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 6:33:26 PM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The recall of Ramipril 5mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market position in the cardiovascular segment. This situation requires close monitoring to assess potential impacts on sales forecasts and regulatory compliance. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this recall on sales forecasts and consider potential supply chain disruptions. The strongest clinical anchor is A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy (ClinicalTrials.gov), sponsor/company relevance (roche). In Cardiovascular · ACE Inhibitor, 2 regulatory and 4 competitive items passed relevance filtering for Crescent Pharma Limited.

Competitive Pressure

The most relevant competitive pressure comes from Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. (Merck) — sponsor/company relevance (merck). Secondary pressure from Sterling Pharmaceuticals recalls KidNaps Melatonin due to stability issues. This recall may impact Crescent Pharma's reputation and market share in the cardiovascular segment, particularly for ACE inhibitors.

Regulatory Outlook

Regulatory risk is concentrated around Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28 (MHRA). Entity match (crescent pharma limited). Relevant agencies in corpus: MHRA, FDA. The recall may trigger further scrutiny from health authorities, impacting Crescent Pharma's compliance status and future approvals.

Key Risks

Elevated high regulatory exposure for Crescent Pharma Limited could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The recall could lead to a temporary decline in sales and market share for Crescent Pharma, particularly in the competitive ACE inhibitor market.
Neurology · Sleep Disorders · Safety Signal · This recall may impact market confidence in KidNaps and similar melatonin products, potentially benefiting competitors with stable formulations.
Portfolio teams should assess the impact of this recall on sales forecasts and consider potential supply chain disruptions.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the recall process and any regulatory actions taken by health authorities.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAhigh relevance
Entity match (crescent pharma limited)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Functi
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-Pharmacological Factors on Spinal Block Duration
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of Loco-regional Analgesia Following Placement of Erector Spinae Plane Catheter in Addition to Systemic Analgesia in Patients With Thoracic Trauma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Sterling Pharmaceuticals recalls KidNaps Melatonin due to stability issues
Humanexa Signalsmedium relevance
Moderate corpus alignment
Abiomed Issues Correction for Automated Impella Controllers Due to Safety Concerns
Humanexa Signalsmedium relevance
Moderate corpus alignment
mRNA-LNP Vaccine TP0435 Shows Promise Against Syphilis in Animal Models
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Crescent Pharma Limited

Commercial impact

medium

The recall could lead to a temporary decline in sales and market share for Crescent Pharma, particularly in the competitive ACE inhibitor market.

Regulatory impact

high

The recall may trigger further scrutiny from health authorities, impacting Crescent Pharma's compliance status and future approvals.

What to watch

Monitor for updates on the recall process and any regulatory actions taken by health authorities.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.